奥沙利铂联合雷替曲塞治疗结直肠癌肝转移的疗效观察  

Clinical Observation of Raltitrexed Combined with Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastases

作　　者：刘星[1] 薛海鸥[1] 张春梅 

机构地区：[1]辽宁医学院附属第一医院肿瘤科 [2]锦州石化医院,辽宁锦州121001

出　　处：《辽宁医学院学报》2015年第3期29-31,共3页Journal of Liaoning Medical University (LNMU) Bimonthly

摘　　要：目的评价奥沙利铂联合雷替曲塞治疗结直肠癌经一线治疗失败后出现肝转移的近期疗效和毒副反应。方法选取39例晚期结直肠癌患者经FOLFOX、FOLFIRI或XELOX方案化疗后复发出现肝转移患者,奥沙利铂130 mg/m2,第1天静滴,雷替曲塞3 mg/m2,第2天静滴,避凉保温护理3 d,21 d为1周期,每两个周期评估疗效,直至疾病进展或出现不能耐受毒副反应。结果经奥沙利铂联合雷替曲塞治疗后有效率(RR)为28.2%,肿瘤控制率(DCR)为76.9%。毒副反应主要是I^II度的恶心呕吐(56.4%)、转氨酶升高(48.7%)和周围神经毒性(46.2%)。结论结直肠癌患者经FOLFOX、FOLFIRI或XELOX方案化疗后复发出现肝转移,应用奥沙利铂联合雷替曲塞治疗仍然有效,毒副反应可耐受。Objective To investigate the clinical efficacy and safety of raltitrexed combined with oxaliplatin in the treatment of colorectal cancer liver metastases after failure in first - line treatment. Methods A total of 39 colorectal cancer patients with liver metastases were treated by rahitrexed and oxaliplatin after they failed in FOLFOX, 1FOLFIRI or XELOX. They were given oxaliplatin, 130 mg/m2 ivgtt, dl; rahitrexed, 3mg/m2 ivgtt, d2 and cold insulation care, d3, with 21 days as a cycle, until there was evidence of disease progression or intolerance in the treatment. Results After the combined treatment of raltitrexed and oxaliplatin, RR reached 28. 2% , and DCR was 76. 9%. The main side effects were nausea and vomiting, elevated transaminase and peripheral neurotoxicity with incidence rates of 56.4%, 48. 7% and 46. 2% respectively. Conclusion The treatment method, raltitrexed combined with oxaliplatin, after the failure in FOLFOX, FOLFIRI or XELOX proves to effective for colorectal cancer patients with liver metastases, with tolerance to toxicity.

关 键 词：雷替曲塞 奥沙利铂 结直肠癌 肝转移 

分 类 号：R735.3[医药卫生—肿瘤]